Skip to main content
Oral SERD camizestrant prolongs PFS vs. fulvestrant in breast cancer
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Oral SERD camizestrant prolongs PFS vs. fulvestrant in breast cancer
User login
Username
Password
Reset your password
Concept
Lead
score
Breast Cancer
1
1
Advanced and Metastatic Breast Cancer
0
0.81
Hepatocellular Carcinoma
0
0.66
Cancer
0
0.65
Otolaryngology
0
0.64
Breast
0
0.6
Metastasis
0
0.56
Liver Metastases
0
0.55
Biologic Therapy
0
0.53
Retinal Diseases
0
0.53
Targeted Cancer Therapy
0
0.51
Estrogen
0
0.25
Receptors
0
0.25
Arrhythmia
0
0.12
Hospital
0
0.1
Liver
0
0.1
Lung
0
0.1
Sinus Bradycardia
0
0.09
Adjuvant Setting
0
0.05
Bone
0
0.05
Bradycardia
0
0.05
Care and Maintenance of Vision
0
0.05
Chemotherapy
0
0.05
Endocrine Therapy
0
0.05
Eye Floaters
0
0.05
Field of Vision
0
0.05
Grant
0
0.05
Plasma
0
0.05
Sinus
0
0.05
Virginia
0
0.05
Specialty
Lead
score
Hematology-Oncology
1
1
Internal Medicine
0
0.9
Ob/Gyn & Women's Health
0
0.8
Edit Tags